Success Metrics

Clinical Success Rate
37.5%

Based on 3 completed trials

Completion Rate
38%(3/8)
Active Trials
2(13%)
Results Posted
233%(7 trials)
Terminated
5(33%)

Phase Distribution

Ph phase_3
5
33%
Ph phase_1
2
13%
Ph phase_2
7
47%

Phase Distribution

2

Early Stage

7

Mid Stage

5

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
5(35.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

27.3%

3 of 11 finished

Non-Completion Rate

72.7%

8 ended early

Currently Active

2

trials recruiting

Total Trials

15

all time

Status Distribution
Active(2)
Completed(3)
Terminated(8)
Other(2)

Detailed Status

Terminated5
Completed3
Withdrawn3
unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
2
Success Rate
37.5%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (14.3%)
Phase 27 (50.0%)
Phase 35 (35.7%)

Trials by Status

completed320%
withdrawn320%
unknown213%
terminated533%
recruiting213%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT04411225Phase 3

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

Recruiting
NCT05885542Phase 1

SCORE Emerging Adult Cannabis Use & Stress

Recruiting
NCT05600114Phase 2

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Completed
NCT05097651Phase 2

CBD for Sleep in People With HIV

Withdrawn
NCT03196934

Expanded Use of Cannabidiol Oral Solution

Unknown
NCT03336242Phase 2

Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

Terminated
NCT03458416Phase 2

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

Terminated
NCT03355300Phase 2

Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

Terminated
NCT03421496Phase 3

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

Terminated
NCT05803434Phase 2

Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy

Unknown
NCT02551731Phase 2

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Terminated
NCT02318602Phase 3

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Completed
NCT02318563Phase 3

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Withdrawn
NCT02318537Phase 3

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Withdrawn
NCT02324673Phase 1

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15